Efficacy and Safety of Neoadjuvant Chemoradiation Therapy Administered for 5 Versus 2 Weeks for Resectable and Borderline Resectable Pancreatic Cancer-Reference-Cited by-同舟云学术

Efficacy and Safety of Neoadjuvant Chemoradiation Therapy Administered for 5 Versus 2 Weeks for Resectable and Borderline Resectable Pancreatic Cancer

Published:2022-03 Issue:3 Volume:51 Page:269-277
ISSN:1536-4828
Container-title:Pancreas
language:en
Short-container-title:Pancreas

Author:

Suto Hironobu,Okano Keiichi,Oshima Minoru,Ando Yasuhisa,Matsukawa Hiroyuki,Takahashi Shigeo,Shibata Toru,Kamada Hideki,Kobara Hideki,Tsuji Akihito,Masaki Tsutomu,Suzuki Yasuyuki

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Endocrinology,Hepatology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference48 articles.

1. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial;JAMA,2013

2. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer;Br J Cancer,2009

3. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01);Lancet,2016

4. Neoadjuvant therapy for pancreatic cancer: systematic review of postoperative morbidity, mortality, and complications;Am J Clin Oncol,2016

5. A prospective phase II trial of neoadjuvant S-1 with concurrent hypofractionated radiotherapy in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma;Ann Surg Oncol,2017

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relationships between postoperative recurrences and standardized uptake value on 18F-fluorodeoxyglucose-positron emission tomography in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma who underwent curative pancreatic resection after neoadjuvant chemoradiotherapy;Pancreatology;2024-08

2. Tumor location, clinicopathological features, and perioperative and prognostic outcomes in patients who underwent pancreatic resection following neoadjuvant chemoradiotherapy for resectable pancreatic cancer: A retrospective study;Pancreatology;2024-05

3. ENO1 contributes to the gemcitabine resistance of pancreatic cancer through the YAP1 signaling pathway;Molecular Carcinogenesis;2024-03-22

4. Predictive role of the prognostic nutritional index in patients with pancreatic ductal adenocarcinoma who underwent neoadjuvant chemoradiotherapy followed by curative pancreatic resection: A retrospective study using prospectively collected data;Journal of Hepato-Biliary-Pancreatic Sciences;2024-03-10

5. Short- and Long-Term Outcomes of Neoadjuvant Chemoradiotherapy Followed by Pancreatoduodenectomy in Elderly Patients with Resectable and Borderline Resectable Pancreatic Cancer: A Retrospective Study;Journal of Clinical Medicine;2024-02-21